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Estimating Disease Risk with Genetic 
Screening 
Helen O’Neill  
I t is more than a year since the complete sequence of the human genome was publicly announced (International Human Genome Sequencing Consortium, 2001).  The impact of this milestone on medical research is already apparent.  
Scientists are geared up to adopt new experimental approaches in the race to 
combat human disease.  New information flowing from the human genome project 
should fuel a revolution in medical research with wide-ranging implications for 
human health, longevity and employability.  There are very good reasons to 
collect and use all of this information for the benefit of mankind, to improve 
health care and sustain life.  It remains for society to dictate the level of protection 
placed on personal genetic information.  Checks and balances will need to be 
implemented sooner rather than later.  However, the time may come when the 
genetic blueprint of an individual will be viewed no differently to any other 
personal information.  The potential to predict disease risk by genetic screening is 
considered here along with the health and medical benefits which should flow 
from new approaches to medical research fuelled by completion of the human 
genome project.   
Genetics Today 
The science of genetics originated in the mid-1800s with the experiments of 
Gregor Mendel who investigated the inheritance of characteristics in pea plants.  
While the classical genetics experiments of the early 20th century identified many 
inherited traits, it was the discovery of the DNA double helix in 1953 by Watson 
and Crick which led to identification of DNA as the carrier of genetic information.  
All somatic cells in an individual carry genes from both the father and mother and 
these are inherited en bloc on chromosomes.  The human cell has 23 different 
chromosome pairs including an XX pair of sex chromosomes in females and an 
XY pair in the male.  The approximately 30,000 genes carried by the 46 
chromosomes represent the human genome.   
Each chromosome is made up of a string of four different nucleotides or 
bases, making up a four-letter code referred to as the sequence.  For a given gene, 
the nucleotide sequence forms the genetic code, represented by triplets of bases.  
Genes are aligned along this strand, delineated by regions of coding rather than 
non-coding DNA.  Each gene is first transcribed into an RNA intermediate form 
and then the base triplets are translated into amino acids.  The amino acids are 
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joined together in the sequence dictated by the RNA, producing a protein molecule 
that performs a distinct structural or physiological role in the cell.   
Different proteins have different cellular functions.  Each different type of 
cell produces a distinct range of proteins providing all the necessary structural and 
metabolic functions required by the cell.  Different types of cells or cells in 
different stages of development have a distinct pattern of gene expression and 
produce a unique profile of proteins.  There are many examples of this division of 
function between cells.  For example, B lymphocytes, which represent one type of 
white blood cell type, produce antibody molecules which are released into blood 
where they destroy blood-borne pathogens.  In the pancreas, islet cells are 
specialised for production of the insulin protein.  Any gene mutation which leads 
to reduced levels of insulin can precipitate development of diabetes. 
The nucleotide sequence of a given gene can also vary slightly between 
individuals.  This gives rise to allelic variants of the gene.  One example of this is 
the ABO blood group system, where individuals carry either the A, B or O allele 
of a gene encoding a molecule called the glycosyltransferase enzyme.  This 
molecule functions differently in individuals of different A, B, AB and O blood 
types, leading to the addition of variant carbohydrate side chains on a cell surface 
molecule expressed by red blood cells.  The presence of multiple alleles, or 
‘polymorphism’, in a population leads to the existence of variant forms of the one 
protein, most of which will be functionally indistinguishable and retain normal 
function.  Some allelic variants result in proteins which function less well in some 
circumstances than others.  If this protein is critical to cell function it can place an 
individual at risk of disease.   
Some genes have large numbers of alleles.  One example is the HLA antigen 
system encoded by the major histocompatibility gene complex important in tissue 
matching for transplantation.  There are many HLA alleles and some have been 
associated with disease states like ankylosing spondylitis and hereditary 
hemochromatosis.  HLA genes can be sequenced to determine which alleles are 
carried by members of a multigenerational family.  This information can then be 
used to determine the pattern of inheritance and the penetrance of the particular 
disease. 
Similar screening methods are used to determine the pattern of inheritance of 
mutant genes.  Any single base change or deletion in a gene can lead to mutant 
forms which can be inherited and precipitate disease in some family members.  
Genetic screening to determine sequence changes in a gene of interest can 
determine the mode of inheritance of the mutant gene within the family of an 
affected individual.  More drastic mutations can involve chromosomal aberrations 
such as polyploidy (more than two copies of the same chromosome as seen in 
Down’s syndrome) or translocations between different chromosomes.  Once a 
gene mutation has been linked to a particular disease, standard diagnostic tests 
based on gene sequencing can be devised to detect both normal and mutant forms 
of the gene.  Genetic screening can then be extended to the wider population.  In a 
similar vein, genetic screening can involve chromosomal or cytogenetic analysis 
to detect chromosomal abnormalities associated with disease risk.  Genetic 
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screening to determine disease risk is a straightforward task for diseases linked to 
known genes or known chromosomal aberrations.   
The Nature of Inherited Disease 
Monogenic diseases are caused by mutations in single genes leading to production 
of abnormal proteins affecting a vital cell function.  Individuals who inherit the 
mutant form of the gene have a high risk of disease.  The nucleotide sequence of a 
gene can be used to quickly identify individuals at risk of inheriting the disease or 
trait.  Single gene defects precipitating phenotypic changes or disease can be 
easily traced in pedigree studies.  There are four main patterns of inheritance, 
autosomal recessive, autosomal dominant, X-linked recessive and X-linked 
dominant.  Autosomal recessive diseases require a gene copy to be inherited from 
both parents in order to see expression of the disease, while autosomal dominant 
diseases require only one copy.  X-linked recessive diseases, like red-green 
colour-blindness, are usually only seen in males, whereas X-linked dominant 
diseases are found equally in both sexes.  More than 1000 human disorders have a 
genetic component or are inherited to some degree, but most of these are 
extremely rare affecting between one in 104 to 105 people.  Very few (~100) of 
these are due to a single gene defect.   
The majority of diseases with a genetic component are complex diseases 
involving somewhere between 10 and 30 different genes.  The issue of genetic 
screening for detection of disease is not so straightforward.  Most disease states 
are complex or multigenic, involving sets of interacting genes.  Many are also 
multifactorial, having both genetic and environmental cause.  Diabetes is an 
example of a complex disease.  It is genetically determined, with both genetic and 
environmental components and additive small effects contributed by multiple 
genes.  Even common diseases like allergy, heart disease, depression and asthma 
show some evidence of genetic susceptibility but require environmental triggers to 
precipitate disease.   
Propensity to develop some forms of cancer also has a complex genetic and 
environmental basis.  Similarly, capacity to resist infection by a range of 
pathogens including viruses, bacteria and parasites is genetically controlled.  
Another complication is that some disorders cannot easily be attributed to a 
genetic cause.  They can also have variable expressivity giving a range of severity 
from mild to extreme.  In some cases the same disease phenotype (or appearance) 
results from different gene effects.  In other cases, alternate allelic forms of the 
same gene can lead to different phenotypes.  It can be argued that most diseases 
are so complex that ‘they push the current array of molecular genetic analysis to 
their limits’ (Schork, 1997).  Despite our increased capacity for genetic analysis, it 
is not yet possible to develop genetic screening tests for most of these complex 
diseases. 
The immune response plays an overriding role in many disease states.  This is 
the defence system that monitors the body and removes damaged or infected cells.  
Many genetic effects related to complex disease map to genes that control the 
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immune response (Fahrer et al., 2001).  It is well known that an effective immune 
response can alter the course of disease.  It occurs in response to most disease 
states including infection, cancer, autoimmune disease and injury and there is 
increasing evidence that genes controlling immune responsiveness have a major 
influence on the progress and resolution of most diseases.  For example, one of the 
recently mapped genes for diabetes incidence in mice is IL-12B which encodes a 
soluble factor involved in regulation of immune responses involving T 
lymphocytes (Morahan et al., 2001).  The immune response involves networks of 
cells and secreted molecules produced by cells as part of the defence against 
pathogens.  It is vitally important to work out which genes are involved in immune 
response development since a defect in any one immune response gene could be 
manifest in multiple disease states.  Of particular interest are networks of 
regulatory genes in humans which control the immune response.  This type of 
study has enormous potential for development of new drugs which moderate 
immune function and disease resolution. 
Gene Discovery 
Family studies can be readily used to determine whether diseases are inherited and 
have a genetic component.  However, the association or linkage of disease with 
particular genes segregating in that family is a much more complicated process.  
The endpoint of a successful linkage analysis is the discovery of a specific gene(s) 
associated with the disease and determination of the specific function of the 
protein(s) encoded by the gene(s).  New technology developed in the past two 
decades has increased the capacity for gene discovery.   
One tool now commonly used by geneticists is the library of SNPs or single 
nucleotide polymorphisms that have been located throughout the human genome.  
These represent known sites of natural sequence variation in DNA that can be 
detected by sequencing DNA across those regions in different individuals.  A 
genome-wide map of 1.42 million SNPs has now been aligned with the human 
genome sequence (International SNP Map Working Group, 2001).  The nature of 
SNPs makes them particularly suitable for high-throughout genotyping or allele 
identification so that linkage of disease states with SNPs can be easily calculated.  
With the complete sequence of the human genome the ability to link disease states 
with SNPs on known chromosomes has increased enormously.  These will be used 
increasingly to map disease states to specific regions of the genome and to 
particular genes.   
The complete sequence of the human genome has also been aligned and 
integrated with BAC clones (bacterial artificial chromosomes) representing 
regions of chromosomes that have been linked to many disease genes and human 
traits.  (International Human Genome Mapping Consortium, 2001).  This clone-
based map will be used increasingly by geneticists to obtain rapid and accurate 
identification of genes linked to disease.  BAC clones will be used to isolate genes 
of interest for further study.  Once candidate genes are defined it will then be 
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important to define the products of those genes and to develop strategies to alter 
their aberrant effects.   
While the sequencing of the human genome has led to the identification of 
many genes, the function of most genes remains unknown.  One of the major 
challenges facing geneticists is the characterisation of the proteins produced by all 
genes in the human genome.  It will also be important to work out how genes 
interact and regulate each other.  Complex regulatory networks of genes have been 
described which involve a number of regulatory proteins influencing expression of 
sets of genes (Wyrick and Young, 2002).  These networks are very important in 
development and act to govern gene expression as the organism acquires new 
form and function through its life cycle.  An understanding of the interactions 
involved in complex regulatory networks represents a very challenging area of 
genetics. 
Functional Genomics 
Various experimental approaches can be taken to assess gene function.  The 
pursuit of information on how genes are expressed and interact to give the 
phenotype or appearance of an individual has been called ‘functional genomics’ or 
‘phenomics’.  For complex diseases like diabetes, functional genomic studies aim 
to determine all genes contributing to the diabetic phenotype and to assess 
quantitative and regulatory aspects of gene expression.  This same approach will 
be needed to assess gene function and expression in all diseases including 
different types of cancers.   
One current activity of widespread interest is the gene profiling of cancers 
and diseased tissues.  This involves analysis of the expression level of all genes 
within affected cancer cells.  This analysis utilises small glass slides called micro-
arrays which are dotted with an ordered pattern of probes.  These probes represent 
short sequences of DNA called oligonucleotides representing short sequences of 
known genes.  Micro-arrays are exposed to labeled RNA prepared from tissue.  
The binding or hybridization of a labelled RNA molecule to particular 
oligonucleotide probes will indicate gene expression within the tissue of interest.   
Micro-arrays containing myriads of oligonucleotide probes specific for genes 
of interest allow simultaneous quantitation of RNA related to genes expressed in 
tissues or cancers from affected individuals.  Custom-made micro-arrays can be 
designed to measure expression of genes related to infection with various 
pathogens.  Micro-array data can also be used in cluster analysis to identify 
coincident gene expression and to map out gene networks under the control of 
common regulators.   
The use of animal models is essential in order to proceed to the next step of 
linking genes with particular disease states and gene functions.  This can involve 
‘reverse genetics’ technology and the production of genetically engineered mouse 
strains.  Transgenic mice are developed by transfer of new genes into the DNA or 
genome of a mouse.  From this altered mouse a new inbred strain can be 
developed to study the effect of expression of the introduced gene on the 
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phenotype or characteristics of the animal.  Similarly, ‘knockout mice’ are 
produced by mutating genes in order to study the effect of loss of gene expression 
on the phenotype of the animal.  Other studies can include introduction of marked 
genes into isolated cells in culture using DNA vectors which facilitate new gene 
expression inside cells.  The effect of introduced genes which are expressed within 
cells can be used to make predictions about gene function. 
While these approaches give valuable information, ‘forward genetic 
strategies’ in which random genes are mutated offer a faster approach to 
identification of gene function.  A number of large-scale mouse mutagenesis 
projects are now being conducted to develop a range of mouse mutants that can be 
used to study the effect of gene loss on animal development and disease states.   
This approach is essential to add function to genes in the mouse genome that 
are linked to disease.  Since many genes in mice have homologous or equivalent 
genes in humans it will be a straightforward progression to translate information 
obtained in mouse mutants to the human genome and to define a function for 
genes important in human disease states.  In this procedure, male mice are 
mutagenised to produce single nucleotide mutations in genes with a view to 
breeding multiple mutant mouse strains.  Mice showing phenotypes or diseases of 
importance are selected for further breeding, pedigree analysis and mapping of 
their mutated genes by linkage with SNPs.  The complete sequence of the mouse 
genome is available, along with overlapping sequence and linkage maps for all the 
mouse chromosomes.   
Using these tools, it will be possible to identify candidate genes controlling 
disease and to make predictions about the loss function of mutated genes and the 
nature of the proteins responsible for producing the disease state.  For example, 
mice have been reported which are characteristically obese, diabetic, 
immunodeficient or which develop cancers at an early age (Justice, 2000).  Many 
linkage studies to identify candidate genes are underway. 
From the sequence of the human genome, we can now predict how much of 
the DNA contributes to protein production.  In the human cell only about 1% of 
DNA is actually coding DNA which gives rise to proteins.  The remainder of the 
genome consists of intergenic and intragenic non-coding DNA, most of which has 
unknown or unmapped function in the cell.  There is increasing interest in the 
RNA transcribed from non-coding regions.  Regulatory RNA produced from 
intergenic regions is now thought to influence the production of proteins (Mattick 
and Gagen, 2001), although the mechanisms by which this occurs are not well 
understood.  This type of information removes the emphasis on proteins as the 
controlling elements of cell differentiation.  The enormous potential for regulatory 
effects due to interactions between RNA and between RNA and proteins or DNA 
is almost beyond comprehension.  It represents an area of genomics that extends 
beyond the scope of current molecular biology.   
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Contribution of Genomics to Human Health 
The human genome project will almost certainly increase our capacity for 
improved genetic screening to determine carriers of genes linked to serious 
disease.  Two new technologies appear to offer the greatest potential for 
identification of susceptibility genes.  These are SNP typing and the use of micro-
arrays coated with oligonucleotides representing the variant forms of genes.  
Custom-micro-arrays could be used increasingly to identify individual genes 
directly affected by known mutations.  They could also be used to determine gene 
expression changes resulting from those mutations.  The development of a 
comprehensive list of disease genes and definition of their function will link 
genetics with medicine and precipitate new approaches to medical research. 
As more genes are mapped and their functions defined, the capacity to 
develop drugs and therapeutic strategies to halt or reverse disease states should 
increase.  Once the protein product of a gene is known, new drugs can be designed 
to specifically block protein function.  The field of pharmacogenomics, involving 
development of drugs based on genes that determine disease, will expand.  It may 
also be possible to develop individualised treatment based on the disease genes 
carried by an individual.  For example, individuals could be screened for genes 
determining sensitivity to certain drugs.  This could allow more accurate 
determination of drug dose and type so that therapy for cancer can be more 
accurately applied resulting in more effective treatment and fewer side-effects. 
One important area will be the definition of the genes determining 
susceptibility to infection.  Pathogens are probably the greatest threat to human 
health and longevity.  There will be increased information on genes determining 
immune response potential and capacity to overcome infection.  New 
immunoregulatory molecules will be defined and exploited for their potential use 
in immunotherapy.  It is expected that some genes determining immune response 
to infection will be associated with a number of different diseases.  Along with the 
discovery of new genes controlling the immune response will come increased 
opportunity to design vaccines to induce immunity and prevent infection.  
Preventative medicine may become available to individuals genetically more 
susceptible to certain types of infection.   
Continual investigation will be needed to gauge the impact of infection on the 
human genome since the genetic basis of disease susceptibility can change as new 
pathogenic variants arise due to mutation of rapidly dividing micro-organisms.  
While most vaccines will be directed against infectious diseases, the potential 
exists to develop vaccines against other complex diseases such as autoimmune 
diseases and cancers.  Another important area of investigation will be the impact 
of infectious agents on the manifestation of diseases with a known genetic 
component.  For example, previous infection is thought to be associated with the 
development of some diseases.  Associations have noted between rotavirus 
infection and development of diabetes, retrovirus infection with multiple sclerosis 
and Epstein Barr virus with chronic fatigue syndrome.   
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The mutant forms of many genes are already known to contribute to cancer.  
The human genome sequence can be used to identify genes similar to or 
representing partial homologues of known cancer genes.  Another approach is to 
fingerprint cancers to identify their gene expression profile.  Using micro-array 
technology, it is possible to produce gene expression profiles for each of the 
different types of cancers (Alizadeh and Staudt, 2000).  By comparing profiles of 
cancer cells with the normal non-cancerous cell counterpart, genes specifically 
expressed in the cancer can be identified.  Mutations in gene products and copy 
number differences can be detected along with genes in the downstream pathways 
responsible for the defective phenotype.  The new Cancer Genome Anatomy 
Project (Strausberg et al., 2001) aims to accelerate the field of cancer genomics by 
producing an online database of all gene expression data related to cancers.   
Concluding Remarks  
The capacity to perform rapid and multiple genetic screening tests will increase 
with the availability of the human genome sequence and associated linkage maps.  
Screening tests can be easily designed to detect small mutational differences 
between alleles in different individuals and to make predictions about disease risk 
associated with different genes and their allelic and mutant forms.   
However, despite enormous technical advances, the very complexity of 
diseases with a genetic component remains a major inhibiting factor for 
development of routine genetic screening strategies to determine risk for the 
majority of diseases.  Another important issue is that genetic information alone 
does not have predictive value for disease.  Environment, lifestyle and infectious 
disease also impact on the manifestation of genetically determined disease.  The 
main conclusion from this paper is that while it is now easy to establish diagnostic 
genetic screening tests, these will not tell us much about risk for the majority of 
diseases which are complex and for which there is significant environmental 
dependency.   
Genetic testing will not be predictive for multigenic, multifactorial diseases 
until scientists understand the function of all genes and map out the interacting 
networks between those genes.  The problem facing scientists relates to the sheer 
number of genes and environmental factors impacting on disease expression.  The 
full impact of the human genome project will not be felt for decades.  ‘The Human 
Genome Project will not be completed …until the functions of all human genes 
have been determined’ (Sutherland, p.594). 
Understandably, people are concerned about issues related to genetic 
screening and the impact it could have on their privacy, health and financial 
situation.  The problem with genetic data relates to its familial nature.  People will 
remain sensitive about the need to disclose personal genetic information to 
insurers.  The laws controlling privacy of genetic information will need to be 
protective but adaptable to meet the needs of individuals, researchers and 
insurance companies.  Adaptability will be important because the development of 
knowledge may well accelerate with time.  Information disclosure may become a 
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lesser problem as the functions of more genes are defined.  Institutions offering 
life and medical insurance will need to consider how all of this new information 
will affect the type of policies they can offer to different risk classes at different 
premiums. 
One prediction is that multiple genes will be associated with risk for most 
diseases.  In the long run it may be possible to assign a value of risk to each gene 
linked to a particular disease.  People may be faced with the decision to undergo 
genetic screening to assess their disease risk and to make lifestyle choices, or to 
undergo a variety of medical treatments.  Longevity should increase with the 
availability of new preventative and therapeutic medicines  (Sutherland, 2000).  
The nature of health and life insurance products could be quite different from 
those available today.  People will still want insurance but the industry will need 
to adjust to meet consumer needs.   
Actuaries will need to keep abreast of new developments in genetics in order 
to price insurance and make it available to most individuals.  Once a risk is 
assigned to every gene in an individual for every known disease, then it is hard to 
see how life insurance as we know it will exist.  The issue for actuaries and 
insurers may well be development of new products that guard against unforeseen 
factors like major environmental shifts or the occurrence of catastrophic genetic 
change.  These are events that cannot be predicted given current knowledge.  This 
process of change will depend on the accessibility of information under regulated 
circumstances.   
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